NFSG
HRTX icon

Newbridge Financial Services Group’s Heron Therapeutics HRTX Stock Holding History

Newbridge Financial Services Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,860
Closed -$73K – 1471
2021
Q3 		$73K Buy
+6,860
New +$83.5K 0.05% 320
2021
Q2 		– Sell
-500
Closed -$8K – 1461
2021
Q1 		$8K Hold
500
– – 0.01% 947
2020
Q4 		$11K Buy
+500
New +$8.69K 0.01% 693

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Newbridge Financial Services Group's HRTX Position: Q4 2021 in Review

Newbridge Financial Services Group sold out of Heron Therapeutics (HRTX) in Q4 2021, closing a stake of 6,860 shares — an estimated $73K sold.

Newbridge Financial Services Group first reported a position in HRTX in Q4 2020 and held it in 3 quarters. The position peaked at $73K in Q3 2021. 200 funds tracked by Wall St. Rank hold HRTX as of Q4 2021.

  • Newbridge Financial Services Group reported no remaining Heron Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Newbridge Financial Services Group sold 6,860 Heron Therapeutics shares in Q4 2021, an estimated $73K.
  • Newbridge Financial Services Group first reported a position in Heron Therapeutics in Q4 2020 and held it in 3 quarters.
  • Newbridge Financial Services Group's Heron Therapeutics position peaked at $73K in Q3 2021.
  • 200 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2021.

Based on Newbridge Financial Services Group's 13F filing for Q4 2021, filed 19 Jan 2022.